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3ABSTRACT
The GABAB receptor is well recognized as being composed of two subunits, GABAB1
and GABAB2. Both subunits share structural homology with other class-III G protein-coupled
receptors (GPCRs). They are composed of two main domains, a heptahelical domain (HD)
typical of all GPCRs and a large extracellular domain (ECD). Although GABAB1 binds
GABA, GABAB2 is required for GABAB1 to reach the cell surface. However, it is still not
demonstrated whether the association of these two subunits is always required for function in
the brain. Indeed, GABAB2 plays a major role in the coupling of the heteromer to G proteins,
such that it is possible that GABAB2 can transmit a signal in the absence of GABAB1. Today
only ligands interacting with GABAB1 ECD have been identified. Thus compounds acting
exclusively on the GABAB2 subunit will be helpful in analyzing the specific role of this
subunit in the brain. Here, we explored the mechanism of action of CGP7930, a compound
described as a positive allosteric regulator of the GABAB receptor. We showed that it
activates the wild type GABAB receptor, though with a low efficacy, the GABAB2 HD being
necessary for this effect, although one can not exclude that CGP7930 could also bind to
GABAB1. Of interest, CGP7930 could activate GABAB2 expressed alone, and is the first
described agonist of GABAB2. Finally, we show that CGP7930 retains its agonist activity on a
GABAB2 subunit deleted of its ECD. This demonstrates the HD of GABAB2 behaves like a
rhodopsin-like receptor, as it can reach the cell surface alone, can couple to G-protein and be
activated by agonists. These data open new strategies for studying the mechanism of
activation of GABAB receptor and examine any possible role of homomeric GABAB2
receptors.
4The GABAB receptor is a G protein-coupled receptor (GPCR) activated by the most
abundant inhibitory neurotransmitter of the central nervous system, γ-amino butyric acid
(GABA). This receptor is involved in numerous physiological processes via the regulation of
both GABAergic and glutamatergic synapses at either the pre- or post-synaptic level (1).
Accordingly, GABAB receptors are involved in various types of epilepsy, in nociception and
drug addiction, and in spasticity associated with multiple sclerosis (2). Although it has been
pharmacologically described for twenty years, only in 1998 was the first GABAB receptor
(GABAB1) cloned (3). It belonged to the class-III of the GPCR super family, together with the
metabotropic glutamate (mGlu), the calcium sensing (CaS), and some pheromone and taste
receptors (4). In addition to the typical GPCR heptahelical domain (HD), GABAB1 possesses
a large extracellular domain (ECD), like most other class-III GPCRs (4). In contrast to the
rhodopsin-like receptors (class-I GPCRs), the ligand binding site of class-III GPCRs is
located within their large ECD, in the so-called Venus Fly-Trap Module (VFTM). Indeed,
agonists bind within a cleft that separates the two lobes of the VFTM and stabilize a closed
active conformation. This has been recently illustrated by the crystal structures of the mGlu1
ECD that have been solved both in the absence and presence of agonist (5), and confirmed in
the case of GABAB1 by multiple mutagenesis studies (6-8).
However, to form a receptor able to efficiently activate G-proteins, GABAB1 need to
be associated with a homologous protein called GABAB2 (9-13). GABAB receptor was then
the first described obligatory heterodimeric receptor. Several studies unraveled some specific
roles dedicated to each subunit. First, GABAB2 takes GABAB1 to the cell surface probably by
masking a retention signal located in GABAB1 C-terminal tail (14-16). Secondly, GABAB1
VFTM, but not that of GABAB2, binds all known GABAB agonists and antagonists, whereas
GABAB2 HD is critical for G protein activation (17-20). Third, there are complex allosteric
interactions between the ECD and the HD of both subunits (20-22) leading to optimal agonist
affinity and coupling efficacy.
Although the co-expression of both GABAB1 and GABAB2 appears to be required for
an efficient activation of G-proteins, some studies report a possible functioning of one
GABAB subunit independently of the other (9). (23). In support of a functional role of
GABAB2 in the absence of GABAB1, homodimeric GABAB2 receptors have been observed at
the surface of heterologous cells (24), and homodimeric GABAB2 HDs are capable of
activating G-proteins (20,21). Moreover, localization studies revealed that some neurons in
5the brain express much more mRNA of one subunit than of the other consistent with a
possible role of homomeric GABAB receptors (25). Finally, GABAB1 may be able to activate
intracellular pathways independently of G-proteins (23,26-28). The identification of selective
compounds acting on GABAB2 will probably help unravel this issue.
Within the last few years, allosteric modulators of class-III GPCRs have been
identified for CaS and mGlu receptors (29-31). Such compounds act either as non-competitive
antagonists (32-34), or as positive allosteric modulators (35-40). In each case, these
compounds have been shown to bind within the HD of their targeted receptor (34,41-43).
They are also highly selective for one receptor subtype, in contrast to most of the ligand
acting at the orthosteric site. Urwyler and coll. recently described the first GABAB specific
positive allosteric modulators, CGP7930 and CGP13501 and more recently the compound
GS39783 (44,45). Their site of action was not identified, but according to what was known
for the mGlu specific positive allosteric modulators and to the fact that GABAB2 coupled to G
protein, we hypothesized that these compounds act in the GABAB2 HD (46).
In the present work, we not only demonstrate that CGP7930 indeed modulates the
GABAB receptor by directly acting in the GABAB2 HD, but also that it activates the
homomeric GABAB2 receptor, indicating that GABAB2 could be functional by itself.
Moreover, CGP7930 also activates a truncated version of GABAB2 deleted of the ECD,
demonstrating that this HD can behave like a rhodopsin-like receptor. These data bring much
information on the mechanism of action of this GABAB positive modulator and reveal that
GABAB2 selective drugs can be identified. Such drugs will be useful to better dissect the
specific role of GABAB1 and GABAB2 in the brain.
6MATERIALS AND METHODS
Materials
Aldehyde CGP13501 was synthetized according to FR2237870 patent and was
subsequently reduced with sodium borohydride to afford CGP7930 (mp. 82-84°C,
US4333868 patent 86°C).
CGP54626 was purchased from Tocris (Fisher-Bioblock, Illkrich, France). Fetal
bovine serum (FBS), culture media and other solutions used for cell culture were from
GIBCO-BRL-Life Technologies, Inc. (Cergy Pontoise, France). [
3
H]-myo-inositol (23.4
Ci/mol) was purchased from Perkin–Elmer Life Science (NEN) (Paris, France). All other
reagents used were of molecular or analytical grade where appropriate.
Plasmids and site-directed mutagenesis
The plasmids encoding the wild-type and chimeric GABAB1a and GABAB2 subunits
epitope tagged at their N-terminal ends (pRK-GABAB1a-HA, pRK-GABAB1a/2-HA, pRK-
GABAB2/1-HA and pRK-GABAB2-HA or -cMyc), under the control of a CMV promoter, were
previously described (16,20). PRK-HD2 was generated by deletion of the sequence coding for
the ECD in the pRK-GABAB2-HA plasmid, with the use of the MluI restriction site located
just after the sequence coding for the HA tag and a MluI site created just after the proline
residues at position 463 in GABAB2.
Cell culture and transfection
Human embryonic kidney (HEK) 293 cells were cultured in Dulbecco’s modified
Eagle’s medium supplemented with 10% FCS and transfected by electroporation as described
elsewhere (47,48). Unless stated otherwise, 10.10
6
 cells were transfected with plasmid DNA
containing the coding sequence of the receptor subunits, and completed to total amount of
10 µg plasmid DNA with pRK6. For determination of inositol phosphate accumulation, the
cells were also tranfected with the chimeric Gαqi9 G-protein which allows the coupling of the
recombinant heteromeric GABAB receptor to PLC (47).
7Measurement of inositol phosphate production
Determination of inositol phosphate (IP) accumulation in transfected cells was
performed in 96-wells plates (0.2.10
6
 cells/well) after over-night labeling with 
3
H-myo-
inositols (0.5µCi/well) as already described (49). The stimulation was conducted for 30
minutes in a medium containing 10mM LiCl and the indicated concentration of agonist or
antagonist. The reaction was stopped with a 0.1M formic acid solution. Supernatants were
recovered and IP were purified by ion exchange chromatography using DOWEX AG1-X8
resin (Biorad, Marnes-la-Coquette, France) in 96 well filter plates (ref: MAHVN4550
Millipore, Bedford, MA). Total radioactivity remaining in the membrane fractions was
counted after treatment of cells with a solution containing 10% triton X-100 and 0.1N NaOH.
Radioactivity was quantified using Wallac 1450 MicroBeta liquid scintillation counter. Data
were expressed as IP/Membrane, meaning the amount of total IPs produced over the amount
of radioactivity remaining in the membranes, multiplied by 100. Unless stated otherwise, all
data are means ± sem of at least 3 independent experiments. The dose-response curves were
fitted using the Kaleidagraph program and the following equation "y=[(ymax-
ymin)/(1+(x/EC50)
nH
)) +ymin" where the EC50 is the concentration of the compound necessary
to obtain 50% of the maximal effect and nH is the Hill coefficient.
Anti-HA ELISA for quantification of cell surface expression
Twenty-four hours after transfection (10.10
6
 cells, HA-tagged GABAB1 (2µg) and
cMyc-tagged GABAB2 (2µg) subunits), cells were fixed with 4% paraformaldehyde and then
blocked with PBS + 5% FBS. After 30 minutes reaction with primary antibody (monoclonal
anti-HA clone 3F10 (Roche, Basel, Switzerland) at 0.5µg/mL) in the same buffer, the goat
Anti-Rat antibody coupled to horseradish peroxidase (Jackson Immunoresearch, West Grove,
PA) was applied for 30 minutes at 1µg/mL. After intense washes with PBS, secondary
antibody was detected and quantified instantaneously by chemiluminescence using
Supersignal ELISA femto maximum sensitivity substrate (Pierce, Rockford, IL) and a
Wallac Victor
2
 luminescence counter.
8GTP- -[
35
S] binding measurements
Cells were transfected using PolyFect transfection reagent (Qiagen, Hilden, Germany)
under optimized conditions. Complex were formed using total amount of 8µg plasmid DNA
with 60µL of polyfect in 300µL of serum free antibiotic free DMEM for 10 minutes and then
added to cells at 40-60% confluence. According expression results, the amount of DNA is
GABAB1 2µg, GABAB2 1µg, Gαo1c 2µg and pRK6 3µg for wild-type receptor. Forty-eight
hours after transfection, cells were scraped in lysis buffer (15mM Tris, 2mM MgCl2, 0.3mM
EDTA pH 7.4) and centrifuged twice. The pellet was solubilised in Tris (50mM) MgCl2
(3mM) buffer pH 7.4 using a potter. The GTP-γ-[35S] binding was performed in 96-wells
filtration plates (ref: MAFCN0B50, Millipore, Bedford, MA) equilibrated with Tris (50mM)
MgCl2 (5mM) pH7.4. 5µg of membrane preparation per wells were pre-incubated in 20µL
with antagonist (15 minutes) and after with agonist (15 minutes). 60µL of incubation buffer
(50mM Tris, 1mM EDTA, 10µM GDP, 5mM MgCl2, 0.01mg/mL leupeptine, 100mM NaCl),
and 20µL of H2O per well were added, and then, the plate was incubated one hour at 30°C.
After vacuum filtration and plate filter drying, the radioactivity was measured using a Wallac
1450 MicroBeta liquid scintillation counter. The dose-response curves were fitted using the
Kaleidagraph program and the following equation "y=[(ymax-ymin)/(1+(x/EC50)
nH
)) +ymin"
where the EC50 is the concentration of the compound necessary to obtain 50% of the maximal
effect and nH is the Hill coefficient.
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CGP7930 is a positive allosteric modulator of the GABAB receptor
As previously described by Urwyler et al., CGP7930 increased both the affinity and
the maximal effect (about 40%) of GABA in stimulating GTP-γ[35S] binding on Gαo-proteins
(Fig.1) (44). Dose-response curves indicate the EC50 for GABA was increased 3- and 10-fold
in the presence of 0.1 and 1mM CGP7930, respectively (42.0 ± 11.0; 30.0 ± 7.5 and 4.7 ±
1.04 µM, in the absence or in the presence of 0.1mM and 1mM CGP7930, respectively). A
small increase in the binding of GTP-γ[35S] binding was also observed in the absence of
GABA, suggesting that CGP7930 may also be able to slightly activate the receptor. However,
such an effect of CGP7930 could not be studied in details using this assay according to the
high basal GTP-γ[35S] binding, and to the low signal to noise ratio of this assay (2 to 3 fold
increase observed with a saturating GABA concentration).
Therefore, the effect of CGP7930 was further analyzed using an IP production assay
which is supposed to give a higher signal to noise ratio. Indeed the GABAB receptor can
efficiently activate PLC when co-expressed with the chimeric G-protein Gqi9 (47). As
previously noticed, the IP assay is much more sensitive than the GTP-γ[35S] assay as indicated
by the 100 fold lower EC50 value measured for GABA compare to the GTP-γ[35S] assay. This
likely results from the large amplification of the signaling cascade between G-protein
activation and IP formation.
As observed with the GTP-γ[35S] assay, 100 µM CGP7930 increased GABA potency
in stimulating IP formation 3 fold (EC50: 0.32 ± 0.10 µM and 0.11 ± 0.02 µM, in the absence
and presence of 100 µM CGP7930, respectively), as well as the maximal effect (Fig.2 and
3A). The EC50 for this effect of CGP7930, as determined by increasing concentrations of this
compound in the presence of a fixed concentration of GABA was similar to that determined
by Urwyler et al. when using a IP-induced Calcium signal assay (18,9 ± 7,7 and 10 ± 0.1 µM
respectively) (44).
However, in this assay, CGP7930 also clearly stimulated IP production even in the
absence of added GABA, further suggesting that the CGP7930 could be a GABAB partial
agonist (Fig.2 and 3).
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CGP7930 is a partial agonist of the GABAB receptor
Additional experiments were performed in order to demonstrate that CGP7930 directly
activates the GABAB receptor. First, CGP7930 alone did not induce IP formation in pRK6
and Gqi9 transfected control cells, nor in cells co-expressing mGlu5, demonstrating that IP
production did not result from a direct action on either the transfected G-protein or PLC (data
not shown). Second, the observed stimulation of IP production by CGP7930 (Fig.3A), is
dose-dependent with an EC50 similar to that observed for the potentiating effect (32.5 ± 7.2
µM; Fig.4).
As we could not exclude that the observed effect of CGP7930 was du to over-
expression of the receptors, we decided to examine the effect of CGP7930 at different
receptor expression levels. To that aim the effect of saturating concentrations of GABA or
CGP7930 (1mM) were measured in cells transfected with increasing amount of GABAB1- and
GABAB2-expressing plasmids (Fig.5). The expression levels of heteromeric GABAB receptor
were determined using ELISA performed on intact cells with an anti-HA antibody labeling
the N-terminal HA-tagged GABAB1 subunit. As shown in Fig.5, the maximal agonist activity
of CGP7930 was always lower than the maximal GABA activity, and of course than the
maximal activity induced by CGP7930 together with GABA, indicating that CGP7930 was
only a partial agonist.
The heptahelical domain of GB2 is required for the action of CGP7930
In order to identify the site of action of CGP7930, we first examined whether the
stimulatory effect was inhibited by the competitive antagonist CGP54626. As shown in
Fig.3B, high concentration of (1 µM, about 250 fold its affinity) totally antagonized the effect
of GABA, both compounds binding in the same site in the ECD of GABAB1. However,
CGP54626 did not completely inhibited (57.5 ± 0.5 % of inhibition) the effect of CGP7930.
This suggested that CGP7930 did not bind in the orthosteric site where GABA and
competitive antagonists bind within the GABAB1 ECD, but in another domain, in an allosteric
site. Thus, CGP54626 probably allosterically inhibited the CGP7930 effect.
GABAB heterodimers can be considered as the association of 4 distinct domains
(ECD1, ECD2, HD1 and HD2) that correspond to the ECD and HD of GABAB1 and GABAB2
subunits, respectively. To identify which of these domains is required for the effect of
CGP7930 its action on various combinations of chimeric and mutated subunits was examined.
The chimeric subunits used were GABAB1/2 and GABAB2/1, in which the entire ECD have
been swapped between GABAB1 and GABAB2 (20).
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The GABAB1/2 was expressed with GABAB1 to form a receptor that does not contain
the ECD2, and vice-versa, GABAB2/1 was expressed with GABAB2 to form a receptor devoid
of ECD1. Both combinations have already been shown to be expressed at the cell surface and
to form heteromeric complexes (20). Although they are not sensitive to GABA, both activate
Gqi9, as illustrated by the high constitutive IP formation measured in cells expressing these
subunit combinations (20). As shown in Fig.6, CGP7930 stimulated IP production in cells
expressing either combination (Fig.6, compare lanes 3 and 6). Accordingly, none of the ECD
was required for the effect of CGP7930. Then, although we could not rule out that CGP7930
could act similarly on both ECD1 and ECD2 and that only one ECD would be enough for the
effect of CGP7930, the more likely possibility was that CGP7930 acts in the HD of either
GABAB1 or GABAB2.
In order to determine which HD could be the site of action of CGP7930, the effect of
CGP7930 was analyzed on the combinations GABAB1 + GABAB2/1 and GABAB2 +
GABAB1/2. The first combination possessed only HD1 and not HD2, whereas the second
possessed HD2 only and not HD1 (Fig.7). In order to allow the correct expression of both
GABAB1 and GABAB2/1 at the cell surface, the ER retention signal RSR located in the C-
terminal tail of these subunits was mutated into ASA (20). Although the combination
GABAB1 + GABAB2/1 was not activated by GABA, whereas the combination GABAB2 +
GABAB1/2 was, both combinations were similarly expressed at the cell surface ((20) and data
not shown). As shown in Fig. 7, CGP7930 stimulated the combination containing only HD2
(4 fold increase of the IP production, from 4.7 to 13.8 normalized cpm in the absence and
presence of 100µM CGP7930, respectively), but was devoid of activity on that possessing
HD1 only. Taken together, these data illustrated the requirement of HD2 for the partial
agonist activity of CGP7930 in the GABAB heteromer. However, because GABAB1 cannot
activate the G protein by itself, one can not exclude that CGP7930 bound to GABAB1 but
failed at allowing it to stimulate G proteins.
CGP7930 activated GABAB2 in the absence of GABAB1
As mentioned above, GABAB2 possesses sufficient molecular determinants for G-
protein activation (17-20). Even when transfected alone, GABAB2 was highly expressed at the
HEK293 cell surface (Fig.8A), allowing us to examine whether CGP7930 could activate this
subunit expressed alone. Indeed, whereas GABA is devoid of activity on GABAB2, CGP7930
increased IP production 3 fold (Fig.8B) with an EC50 of 57.1 ± 3.8 µM (Fig. 9). A similar
effect of CGP7930 was observed with the chimeric subunit GABAB1/2, even though GABA
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was inactive (Fig.8A and B). This confirms that the HD of GABAB2 is crucial for the
CGP7930 effect. However, it is still possible that CGP7930 requires the presence of an ECD,
either that of GABAB1 or GABAB2, to turn on the GABAB2 HD.
CGP7930 activated GABAB2 HD (HD2) expressed alone
According to the data described above, it appeared that CGP7930 could activate
GABAB2 by a direct action in its HD. Thus, we looked for the action of CGP7930 on the HD
of GABAB2 alone. Indeed, we have recently shown that the HD of mGlu5 receptor could be
expressed alone and could be directly activated by a positive allosteric modulator of this
receptor (49). We therefore generated a truncated version of GABAB2 lacking the large ECD
(Fig. 8). Thanks to the presence of a signal peptide and of a HA tag inserted at the N-
terminus, HD2 was found at the cell surface, although at a lower level than the wild-type
subunit (30% of the wild type Fig.8A)). On cells expressing HD2, CGP7930 increased IP
production more than two folds, with an EC50 of 64.8 ± 38.7 µM (Fig.9). These data showed
that CGP7930 directly stabilizes an active conformation of the GABAB2 HD, and can be
considered as a first GABAB2 ligand.
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DISCUSSION
In the present study, we explored the mechanism of action of CGP7930, one of the
first described positive allosteric modulators of the GABAB receptor (44). Using both GTP-
γ[35S] binding and IP production assays, that reflect the activation of Gαo and Gαqi9
respectively, we confirmed the positive allosteric action of CGP7930. However, using the
more sensitive IP assay – i.e. activation of PLC via Gαqi9 - CGP7930 was also found to
directly activate the GABAB receptor though with a low efficacy. The action of CGP7930 on
various combinations of wild type and chimeric subunits, led us to propose that CGP7930
activated HD2 within the heteromer. This proposal was then directly demonstrated, as we
showed that CGP7930 acted as an agonist of HD2 expressed alone, demonstrating this
domain of the GABAB receptor behaved like a rhodopsin-like receptor. It is noteworthy that
even if CGP7930 could bind to the HD of GABAB1, it would not induced G protein
activation, as we never observed any activation of the recombinant G-proteins by GABAB
receptors lacking HD2 (17,19,20).
CGP7930, a partial agonist of the GABAB receptor
Not only could CGP7930 potentiate the effect of GABA, as previously reported by
others (44), but it could also directly activate the wild-type receptor. This effect occured in a
similar range of concentration as those observed for the potentiating effect, and various
arguments excluded the possibility of a potentiation of the effect of a possible endogenous
agonist present in the assay medium. Indeed, the effect of CGP7930 was not fully inhibited by
a competitive antagonist. Moreover, the effect of CGP7930 could still be observed on various
mutated GABAB receptors not sensitive to GABA.
Since CGP7930 activated GABAB2 in the absence of GABAB1, then the agonist effect
observed could well be the consequence of some GABAB2 subunits not associated with
GABAB1. Although this possibility can not be firmly excluded, we think it is unlikely since
we and others observed that in heterologous systems GABAB2 was less expressed than
GABAB1 (8,50). Accordingly, it is very unlikely that there was enough isolated GABAB2
subunits (either in a monomeric or homodimeric form) in cells transfected with both GABAB1
and GABAB2 to generate a CGP7930-induced response higher than that observed in cells
expressing GABAB2 only.
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Of interest, CGP7930 activated not only the heteromeric GABAB receptor and the
GABAB2 subunit expressed alone, but also a GABAB2 subunit deleted of its ECD. Moreover,
all these effects were observed in the same range of concentration of CGP7930 (with very
similar EC50 values). This observation clearly indicates that neither GABAB2 ECD nor the
GABAB1 are required for the agonist activity of CGP7930. Also, this further demonstrates
that agonist binding is not required for CGP7930 interaction with HD2.
On a possible allosteric control of CGP7930 effect
The affinity of GABA on the ECD of GABAB1 ass allosterically regulated by the other
domains of the heteromeric GABAB receptor, like the ECD of GABAB2. We recently
hypothesized that this effect was probably due to the relief by the GABAB2 ECD of an
inhibitory action of the GABAB1 HD on the GABAB1 ECD (22). Accordingly, one would
expect that the affinity of CGP7930 in the HD of GABAB2 would also be under the allosteric
control of the other domains of the heteromeric complex. The EC50 of CGP7930 on the wild
type receptor, on GABAB2 or on HD2 were quite similar, whether the agonist effect or the
potentiating effect of CGP7930 was measured. This suggests that CGP7930 affinity was not
as dependent as GABA affinity on the specific state of the other domains. Alternatively,
within this range of concentration tested, CGP7930 may only bind and exert its effect on
receptors in a specific state. The identification of radioactive compounds interacting at the
same site than CGP7930 would be required to further study this point.
However, the antagonist CGP54626 that likely stabilizes the inactive open state of
GABAB1 ECD, partly inhibited the agonist effect of CGP7930 on the wild-type receptor. Such
an effect was not observed on the GABAB2 subunit expressed alone or on HD2. Then this
demonstrated that the action of CGP7930 was dependent of the specific state of the GABAB1
ECD. To our actual knowledge on the mechanism of activation of the GABAB receptor,
GABA binding in the VFT of GABAB1 leads to the closure of the VFT, and to a possible re-
orientation of the dimer of VFTs. As a consequence, this stabilizes the active conformation of
the dimer of HDs. The competitive antagonist like CGP54626 is expected to prevent the
closure of the GABAB1 VFT, and thus to prevent the stabilization of the active state of the HD
dimer by agonists. According to this model, any drug directly stabilizing the dimer of HDs
will also stabilize the active conformation of the dimer of VFTs. In agreement with this
proposal, CGP7930 increased agonist affinity. Due to allosteric coupling between the dimer
of VFTs and the dimer of HD, locking the dimer of VFTs in the inactive state by a
competitive antagonist, are expected to make more difficult the change in conformation of the
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dimer of HDs required for its activation. This is expected to decrease the effect of CGP7930,
as observed here.
.
CGP7930 as an activator of the GABAB2 HD
As recently reported for mGlu5 (49), the HD of GABAB2 could be expressed as a
membrane protein at the cell surface in HEK293 cells. Although the mGlu5 truncated receptor
displayed constitutive activity, no such activity could be detected with GABAB2. This was in
agreement with the higher constitutive activity measured with mGlu5 compared to GABAB
receptor (51,52). However, in both cases, these HDs were activated by positive allosteric
regulators, CGP7930 and DFB for GABAB2 and mGlu5 HDs, respectively. This shows that,
even though class-III and class-I rhodopsin-like GPCRs diverged early during evolution, their
HDs still possess common structural properties and likely share similar activation mechanism.
Whether GPCRs function as monomer or dimers is a matter of intense debate in the
field (53-55). However, in the case of class-III GPCRs it is well accepted that the dimeric
nature of these receptors is crucial for the intra-molecular transduction –i.e. transfer of
information from the agonist binding domain to the heptahelical G-protein activating domain
(4). However, whether a dimeric nature of the HD of these receptors is necessary for the
agonist effect of positive allosteric modulators is not known. Obviously, the demonstration
that HDs of class-III GPCRs can function like class-I GPCRs will help unravel this important
issue.
A model for the action of CGP7930 on the GABAB receptor
We recently proposed a model for the functioning of class-III GPCRs (56). This model
integrated our common view of the functioning of Venus Fly-Trap modules, meaning the
binding of the ligand in the cleft between the two lobes of the ECD, and the stabilization of a
closed state by agonists, or prevention of the closure of such a domain upon antagonist
binding. Moreover, our model takes into account the putative mechanism of activation of the
HD, with the existence of at least two states, active and inactive, the equilibrium between
these two states being under the control of the specific conformation of the ECD. As
discussed in this paper, this model fits very nicely with a series of specific properties of class-
III GPCRs. For example, this model provides a reasonable explanation for the lack of inverse
agonist activity of competitive antagonists of mGluRs, whereas non-competitive antagonists
interacting in the HD were found to be inverse agonists (56).
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In this model, we proposed two options to explain the effect of positive allosteric
modulators acting in the HD of class-III GPCRs. A first possibility is that such compounds act
by stabilizing the active state of the HD, and as a consequence stabilize the active state of the
binding domain therefore increasing agonist affinity. According to this proposal, such positive
allosteric modulators were expected to also activate with a low efficacy the full-length
receptor. This nicely fits with our observation that CGP7930 acted both as an activator and as
a positive allosteric modulator of the full-length GABAB receptor. The second possibility was
that the positive modulators acted by increasing the allosteric coupling between the active
ECD and the HD, rather than by directly activating the HD. According to the second
possibility, the positive modulator directly activated neither the full-length receptor, nor the
HD. Our recent observation that the mGlu5 positive modulator, DFB (3,3’-
Difluorobenzaldazine), did not activate the full-length receptor, but acted as a full agonist on
the receptor deleted of its ECD, did not fit with any of these two possibilities. Accordingly, a
more complex model involving 3 states of the mGlu5 HD was proposed (49). This was based
on the recognized three states of rhodopsin (57,58) Such an observation provides evidence for
a different activation mechanism of GABAB receptors and the other Class-III GPCRs, such as
mGluRs. Indeed, although these two types of receptors share sequence similarities, the
GABAB receptor subunits lack the cystein-rich domain that interconnects the ECD to the HD
in the mGlu-like receptors. Further studies will be necessary to better clarify the specific
properties of both types of class-III GPCRs.
Conclusion
The main observation of this study is that it is possible to identify compounds acting
on the GABAB2 subunit. As discussed above, such compounds will be useful to elucidate the
activation mechanism of such a complex GABAB heteromeric receptor. In addition, as
pointed out in our introduction, it is well recognized that the vast majority of GABAB1 and
GABAB2 subunits associate with each other to form a functional GABAB receptor in the
brain. However, some observations suggest that either GABAB1 or GABAB2 could be active
on their own, or in association with another type of subunit. Our data show that it should be
possible to identify compounds acting on GABAB2 specifically. Such compounds will help
unravel the possible function of this subunit in the brain.
17
Acknowledgements: The authors wish to thank Drs. Julie Kniazeff, Cyril Goudet, Philippe
Rondard, and Thierry Durroux for constructive discussions and critical reading of manuscript.
This work was supported by grants from the CNRS, the Action Incitative "Molécules et
Cibles Thérapeutiques" from INSERM, CNRS and the French government (J.P.P.), and by
Addex Pharmaceuticals (Geneva, Switzerland).
18
REFERENCES
1. Billinton, A., Ige, A. O., Bolam, J. P., White, J. H., Marshall, F. H., and Emson, P. C.
(2001) Trends Neurosci 24, 277-282.
2. Couve, A., Moss, S. J., and Pangalos, M. N. (2000) Mol Cell Neurosci 16, 296-312.
3. Kaupmann, K., Huggel, K., Heid, J., Flor, P. J., Bischoff, S., Mickel, S. J., McMaster,
G., Angst, C., Bittiger, H., Froestl, W., and Bettler, B. (1997) Nature 386, 239-246
4. Pin, J.-P., Galvez, T., and Prezeau, L. (2003) Pharmacol Ther 98, 325-354
5. Kunishima, N., Shimada, Y., Tsuji, Y., Sato, T., Yamamoto, M., Kumasaka, T.,
Nakanishi, S., Jingami, H., and Morikawa, K. (2000) Nature 407, 971-977
6. Galvez, T., Urwyler, S., Prezeau, L., Mosbacher, J., Joly, C., Malitschek, B., Heid, J.,
Brabet, I., Froestl, W., Bettler, B., Kaupmann, K., and Pin, J. P. (2000) Mol
Pharmacol 57, 419-426.
7. Kniazeff, J., Galvez, T., Labesse, G., and Pin, J. P. (2002) J Neurosci 22, 7352-7361.
8. Kniazeff, J., Saintot, P.-P., Goudet, C., Liu, J., Charnet, A., Guillon, G., and Pin, J.-P.
(2004) J. Neuroscience 24, 370-377
9. Kaupmann, K., Malitschek, B., Schuler, V., Heid, J., Froestl, W., Beck, P.,
Mosbacher, J., Bishoff, S., Kulik, A., Shigemoto, R., Karschin, A., and Bettler, B.
(1998) Nature 396, 683-687
10. Kuner, R., Köhr, G., Grünewald, S., Eisenhardt, G., Bach, A., and Kornau, H.-C.
(1999) Science 283, 74-77
11. Ng, G. Y., Clark, J., Coulombe, N., Ethier, N., Hebert, T. E., Sullivan, R., Kargman,
S., Chateauneuf, A., Tsukamoto, N., McDonald, T., Whiting, P., Mezey, E., Johnson,
M. P., Liu, Q., Kolakowski, L. F., Jr., Evans, J. F., Bonner, T. I., and O'Neill, G. P.
(1999) J Biol Chem 274, 7607-7610
12. White, J. H., Alan, W., Main, M. J., Green, A., Fraser, N. J., Disney, G. H., Barnes, A.
A., Emson, P., Foord, S. M., and Marshall, F. H. (1998) Nature 396, 679-682
13. Jones, K. A., Borowsky, B., Tamm, J. A., Craig, D. A., Durkin, M. M., Dai, M., Yao,
W.-J., Johnson, M., Gunwaldsen, C., Huang, L.-Y., Tang, C., Shen, Q., Salon, J. A.,
Morse, K., Laz, T., Smith, K. E., Nagarathnam, D., Noble, S. A., Branchek, T. A., and
Gerald, C. (1998) Nature 396, 674-679
14. Calver, A. R., Robbins, M. J., Cosio, C., Rice, S. Q., Babbs, A. J., Hirst, W. D.,
Boyfield, I., Wood, M. D., Russell, R. B., Price, G. W., Couve, A., Moss, S. J., and
Pangalos, M. N. (2001) J Neurosci 21, 1203-1210.
15. Margeta-Mitrovic, M., Jan, Y. N., and Jan, L. Y. (2000) Neuron 27, 97-106
16. Pagano, A., Rovelli, G., Mosbacher, J., Lohmann, T., Duthey, B., Stauffer, D., Ristig,
D., Schuler, V., Heid, J., Meigel, I., Lampert, C., Stein, T., Prézeau, L., Pin, J.-P.,
Froestl, W., Kuhn, R., Kaupmann, K., and Bettler, B. (2001) J. Neurosci. 21,
1189–1202
19
17. Margeta-Mitrovic, M., Jan, Y. N., and Jan, L. Y. (2001) Proc Natl Acad Sci U S A 98,
14649-14654.
18. Duthey, B., Caudron, S., Perroy, J., Bettler, B., Fagni, L., Pin, J. P., and Prezeau, L.
(2002) J Biol Chem 277, 3236-3241.
19. Robbins, M. J., Calver, A. R., Filippov, A. K., Hirst, W. D., Russell, R. B., Wood, M.
D., Nasir, S., Couve, A., Brown, D. A., Moss, S. J., and Pangalos, M. N. (2001) J
Neurosci 21, 8043-8052.
20. Galvez, T., Duthey, B., Kniazeff, J., Blahos, J., Rovelli, G., Bettler, B., Prezeau, L.,
and Pin, J. P. (2001) Embo J 20, 2152-2159.
21. Havlickova, M., Prezeau, L., Duthey, B., Bettler, B., Pin, J. P., and Blahos, J. (2002)
Mol Pharmacol 62, 343-350.
22. Liu, J., Maurel, D., Etzol, S., Brabet, I., Pin, J.-P., and Rondard, P. (2004) In Press
23. Martin, S. C., Russek, S. J., and Farb, D. H. (1999) Molecular cellular Neurosci. 13,
180-191
24. Maurel, D., Kniazeff, J., Mathis, G., Trinquet, E., Pin, J.-P., and Ansanay, H. (2004)
In Press
25. Calver, A. R., Medhurst, A. D., Robbins, M. J., Charles, K. J., Evans, M. L., Harrison,
D. C., Stammers, M., Hughes, S. A., Hervieu, G., Couve, A., Moss, S. J., Middlemiss,
D. N., and Pangalos, M. N. (2000) Neuroscience 100, 155-170
26. Vernon, E., Meyer, G., Pickard, L., Dev, K., Molnar, E., Collingridge, G. L., and
Henley, J. M. (2001) Mol Cell Neurosci 17, 637-645.
27. White, J. H., McIllhinney, R. A., Wise, A., Ciruela, F., Chan, W. Y., Emson, P. C.,
Billinton, A., and Marshall, F. H. (2000) Proc Natl Acad Sci U S A 97, 13967-13972.
28. Nehring, R. B., Horikawa, H. P., El Far, O., Kneussel, M., Brandstatter, J. H., Stamm,
S., Wischmeyer, E., Betz, H., and Karschin, A. (2000) J Biol Chem 275, 35185-35191.
29. Pin, J.-P., and Acher, F. (2002) Cur. Drug Targets 1, 297-317
30. Gasparini, F., Kuhn, R., and Pin, J. P. (2002) Curr Opin Pharmacol 2, 43-49.
31. Hu, J., and Spiegel, A. M. (2003) Trends Endocrinol Metab 14, 282-288
32. Carroll, F. Y., Stolle, A., Beart, P. M., Voerste, A., Brabet, I., Mauler, F., Joly, C.,
Antonicek, H., Bockaert, J., Müller, T., Pin, J. P., and Prézeau, L. (2001) Mol.
Pharmacol. 59, 965-973
33. Litschig, S., Gasparini, F., Rueegg, D., Stoehr, N., Flor, P. J., Vranesic, I., Prezeau, L.,
Pin, J. P., Thomsen, C., and Kuhn, R. (1999) Mol Pharmacol 55, 453-461
34. Pagano, A., Ruegg, D., Litschig, S., Stoehr, N., Stierlin, C., Heinrich, M., Floersheim,
P., Prezeau, L., Carroll, F., Pin, J. P., Cambria, A., Vranesic, I., Flor, P. J., Gasparini,
F., and Kuhn, R. (2000) J Biol Chem 275, 33750-33758
35. Schaffhauser, H., Rowe, B. A., Morales, S., Chavez-Noriega, L. E., Yin, R., Jachec,
C., Rao, S. P., Bain, G., Pinkerton, A. B., Vernier, J. M., Bristow, L. J., Varney, M.
A., and Daggett, L. P. (2003) Mol Pharmacol 64, 798-810
36. Johnson, M. P., Baez, M., Jagdmann, G. E., Jr., Britton, T. C., Large, T. H., Callagaro,
D. O., Tizzano, J. P., Monn, J. A., and Schoepp, D. D. (2003) J Med Chem 46, 3189-
3192
20
37. Knoflach, F., Mutel, V., Jolidon, S., Kew, J. N., Malherbe, P., Vieira, E., Wichmann,
J., and Kemp, J. A. (2001) Proc Natl Acad Sci U S A 98, 13402-13407.
38. Marino, M. J., Williams, D. L., Jr., O'Brien, J. A., Valenti, O., McDonald, T. P.,
Clements, M. K., Wang, R., DiLella, A. G., Hess, J. F., Kinney, G. G., and Conn, P. J.
(2003) Proc Natl Acad Sci U S A 100, 13668-13673
39. Mathiesen, J. M., Svendsen, N., Brauner-Osborne, H., Thomsen, C., and Ramirez, M.
T. (2003) Br J Pharmacol 138, 1026-1030
40. O'Brien, J. A., Lemaire, W., Chen, T. B., Chang, R. S., Jacobson, M. A., Ha, S. N.,
Lindsley, C. W., Schaffhauser, H. J., Sur, C., Pettibone, D. J., Conn, P. J., and
Williams, D. L., Jr. (2003) Mol Pharmacol 64, 731-740
41. Malherbe, P., Kratochwil, N., Knoflach, F., Zenner, M. T., Kew, J. N., Kratzeisen, C.,
Maerki, H. P., Adam, G., and Mutel, V. (2003) J Biol Chem 278, 8340-8347
42. Malherbe, P., Kratochwil, N., Zenner, M. T., Piussi, J., Diener, C., Kratzeisen, C.,
Fischer, C., and Porter, R. H. (2003) Mol Pharmacol 64, 823-832
43. Lavreysen, H., Janssen, C., Bischoff, F., Langlois, X., Leysen, J. E., and Lesage, A. S.
(2003) Mol Pharmacol 63, 1082-1093
44. Urwyler, S., Mosbacher, j., Lingenhoehl, K., Heid, J., Hofstetter, K., Froestl, W.,
Bettler, B., and Kaupmann, K. (2001) Mol. Pharmacol. 60, 963-971
45. Urwyler, S., Pozza, M. F., Lingenhoehl, K., Mosbacher, J., Lampert, C., Froestl, W.,
Koller, M., and Kaupmann, K. (2003) J Pharmacol Exp Ther 307, 322-330
46. Pin, J. P., Parmentier, M. L., and Prezeau, L. (2001) Mol Pharmacol 60, 881-884.
47. Franek, M., Pagano, A., Kaupmann, K., Bettler, B., Pin, J. P., and Blahos, J. (1999)
Neuropharmacology 38, 1657-1666.
48. Brabet, I., Parmentier, M.-L., Bockaert, J., Acher, F., and Pin, J.-P. (1998)
Neuropharmacology 37, 1043-1051
49. Goudet, C., Gaven, F., Kniazeff, J., Vol, C., Liu, J., Cohen-Gonsaud, M., Acher, F.,
Prezeau, L., and Pin, J. P. (2004) Proc Natl Acad Sci U S A 101, 378-383
50. Couve, A., Filippov, A. K., Connolly, C. N., Bettler, B., Brown, D. A., and Moss, S. J.
(1998) J Biol Chem 273, 26361-26367.
51. Joly, C., Gomeza, J., Brabet, I., Curry, K., Bockaert, J., and Pin, J.-P. (1995) J.
Neurosci. 15, 3970-3981
52. Grunewald, S., Schupp, B. J., Ikeda, S. R., Kuner, R., Steigerwald, F., Kornau, H. C.,
and Kohr, G. (2002) Mol Pharmacol 61, 1070-1080
53. Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., Le
Trong, I., Teller, D. C., Okada, T., Stenkamp, R. E., Yamamoto, M., and Miyano, M.
(2000) Science 289, 739-745
54. Bouvier, M. (2001) Nature Rev. 2, 274-286
55. Chabre, M., Cone, R., and Saibil, H. (2003) Nature 426, 30-31; discussion 31
56. Parmentier, M. L., Prezeau, L., Bockaert, J., and Pin, J. P. (2002) Trends Pharmacol
Sci 23, 268-274.
57. Joubert, L., Claeysen, S., Sebben, M., Bessis, A.-S., Clark, R. D., Martin, R. S.,
Bockaert, J., and Dumuis, A. (2002) J. Biol.  Chem. 277, 25502-25511
21
58. Okada, T., Enrnst, O., Palczewski, K., and Hofmann, K. P. (2001) Trends Biochem Sci
26, 318-324
22
LEGENDES
Figure 1: Concentration-response curves for GABA on wild type GABAB receptor in the
absence (n), or in the presence of 100 µM (O) or 1mM (∆) of CGP7930, generated from a
GTP-γ[35S] binding assay. The GABA EC50 values determined in the absence, and in the
presence of 100 µM or 1mM CGP7930, were 42 µM, 30 µM and 4.7 µM, respectively. The
data were expressed as the % of increase of GTP-γ[35S] binding above basal. The presented
data are from one representative experiment among three experiments performed in triplicate.
Figure 2: Concentration-response curves for GABA on wild type GABAB receptor, generated
from a IP formation assay, in the absence (n), and in the presence of 100 µM of CGP7930
(O). The GABA EC50 values determined in the absence or in the presence of 100 µM
CGP7930 were 0.32 µM and 0.11 µM, respectively. The arrows indicate the EC50 determined
by the curve fits for the conditions without and with CGP7930 respectively. The results are %
of the GABA-induced maximal effect on wild type receptor in the absence of CGP7930. The
presented data are means of five experiments performed in triplicate.
Figure 3: Effect of the CGP7930 (100 µM) and potentiation of the GABA (1 µM) induced-
stimulation of IP formation in absence (A) and in presence (B) of 1 µM of the GABAB
receptor specific competitive antagonist CGP54626. (C) Maximal effects on IP formation
obtained with 1 mM of GABA or 1 mM of CGP7930. The presented data are from one
representative experiment among three experiments performed in triplicate.
Figure 4: Concentration-response curves for CGP7930 generated from the IP formation assay
on wild type GABAB receptor. The EC50 value determined for GABA effect was 32.55 ± 7.23
23
µM. Results are expressed as the % of the CGP7930-induced maximal effect. The presented
data are from one representative experiment among eight experiments performed in triplicate.
Figure 5: Maximal IP formation response depending of the cell surface receptor expression.
IP formation was measured in cells expressing various amounts of the GABAB heterodimer
without drug (¨), or in presence of 1mM of CGP7930 (p), or of 1mM of GABA (Ο), or with
both drugs (u). The receptor expression levels are below the level inducing a saturation of
the transduction machinery, allowing the observation of the increased maximal response
induced by incubation with both compounds, GABA and CGP7930. A.U. stands for Arbitrary
Units. The presented data are from one representative experiment among four experiments
performed in triplicate.
Figure 6: The ECD of GABAB1 or GABAB2 are not required for the effect of CGP7930.
Effect of the CGP7930 (100 µM) in presence or no of GABA (1 mM) on chimeric receptor
formed by the subunit combination GABAB1 + GABAB1/2 and GABAB2 + GABAB2/1, in
which the ECD of GABAB2 and that of GABAB1 is missing respectively. 1 + 1/2 stands for
the subunit combinations GABAB1 + GABAB1/2, and 1/2+2 stands for the subunit combination
GABAB2/1 + GABAB2. CGP7930 was still able to stimulate the IP formation in cells
expressing either combination, indicating that the ECD of GABAB1 or GABAB2 subunits are
not necessary for the effect of CGP7930. The empty circle represents the ECD of GABAB1
and the black circle the ECD of GABAB2, and the empty square represents the HD of
GABAB1 and the black square the HD of GABAB2. The presented data are means of three
experiments performed in triplicate.
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Figure 7: The HD of GABAB2 is required for the effect of CGP7930. The effect of the
CGP7930 (100 µM) was examined, in presence or not of GABA (1 mM), on chimeric
receptors formed by the subunit combination GABAB1ASA + GABAB2/1ASA and GABAB2 +
GABAB1/2, in which the HD of GABAB2 and that of GABAB1 is missing respectively. In these
combinations, the heterodimeric association of the ECD is conserved, but in contrast, the HD
are identical in each combination, displaying then a homomeric HD association.
1ASA+2/1ASA stands for the subunit combinations GABAB1ASA + GABAB2/1ASA, and
1/2+2 stands for the subunit combination GABAB1/2 + GABAB2. The empty circle represents
the ECD of GABAB1 and the black circle the ECD of GABAB2, and the empty square
represents the HD of GABAB1 and the black square the HD of GABAB2. The CGP7930
stimulated only the combination of subunits possessing the HD of GABAB2, indicating that
the HD of GABAB1 was not necessary, in contrast to the HD of GABAB2. The presented data
are means of three experiments performed in triplicate.
Figure 8: A. Cell surface expression of the wild type GABAB receptor, the GABAB2 subunit
alone and the HD2 construct. Using the ELISA procedure, the expression of the different
proteins was determined for each condition and normalized as a percentage of the wild type
GABAB receptor cell surface expression. B. CGP7930 (100 µM) increased the IP production
in cells expressing only the HD of GABAB2. 2, 1/2, and HD2 stand for GABAB2, GABAB1/2
and the HD of GABAB2 respectively. The empty circle represents the ECD of GABAB1 and
the black circle the ECD of GABAB2, and the black square the HD of GABAB2. CGP7930
increased IP formation in cells expressing either the GABAB2 subunit alone or the chimeric
subunit GABAB1/2. Moreover, the HD of GABAB2 expressed alone was stimulated by
CGP7930, confirming that it is enough for the effect of CGP7930. The presented data are
means of four to seven experiments performed in triplicate.
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Figure 9: Concentration-response curves for CGP7930 generated from the IP formation assay
on GABAB2 subunit alone. (A), and on the HD of GABAB2 alone (B). The results are % of the
CGP7930-induced maximal effect on each construct. The EC50 were 57.1 ± 3.8 and 64.7 ±
38.4 µM in cells expressing GABAB2 or the HD of GABAB2, respectively. The black circle
represents the ECD of GABAB2, and the black square the HD of GABAB2. The presented data
are from representative experiments among four experiments performed in triplicate.
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